Colorectal cancer is currently one of the most common malignant diseases and is the leading cause of mortality in the world[@b1]. During the past few decades, the incidence and mortality of colorectal cancer have been increasing rapidly in China[@b2]. The mechanism of this form of carcinogenesis is still not fully understood. Despite environmental agents such as cigarette smoking, dietary, alcohol consumption, and obesity, found to be major risk factors for colorectal cancer, only a fraction of individuals exposed to these factors develop colorectal cancer during their lifetime[@b3][@b4][@b5], suggesting that genetic factors play an important role in the development of colorectal cancer.

DNA is regularly damaged by endogenous and exogenous mutagens. The DNA repair pathways play a vital role in protecting against gene mutation caused by carcinogenesis, among which the nucleotide excision repair (NER) pathway is one of the important DNA repair systems used in correcting localized small lesions and bulky DNA damage[@b6][@b7]. Excision repair cross-complementing group 1 (*ERCC1*) and excision repair cross-complementing group 2/xeroderma pigmentosum group D (*ERCC2*/*XPD*) both are located on chromosome 19q13.3 that participate in the key steps of NER. ERCC1 and ERCC2 are two key rate-limiting enzymes in the multistep NER process. Some studies have suggested that low *ERCC1* expression is associated with increased chemotherapeutic sensitivity and thus considered a predictive marker for patients with colorectal cancer receiving combination oxaliplatin and fluorouracil chemotherapy[@b8], while other studies indicated that genetic variants in *ERCC2* were associated with the increased risk of early relapse in colorectal cancer[@b9]. Single nucleotide polymorphisms (SNPs), as important genetic biomarkers, have been reported to be related with altered gene expression and protein activity. Several SNPs of *ERCC1* and *ERCC2* have been identified, of which *ERCC1* rs11615 and rs3212986 SNPs (Asn118Asn and C8092A) have some effects on *ERCC1* mRNA expression[@b10], whereas *ERCC2* rs1799793 (Asp312Asn) and rs13181 (Lys751Gln) SNPs are associated with suboptimal DNA repair capacity[@b11][@b12]. Given the role of *ERCC1* and *ERCC2* in carcinogenesis, we hypothesized that genetic variations in the *ERCC1* and *ERCC2* genes may confer individual susceptibility to colorectal cancer. Here, we performed a hospital-based case-control study to investigate the association of *ERCC1* and *ERCC2* polymorphisms with the risk of colorectal cancer in a Chinese population.

Results
=======

The distributions of selected variables between cases and controls are summarized in [Table 1](#t1){ref-type="table"}. Briefly, there was no significant differences in the distributions of age (*P* = 0.534), sex (*P* = 0.743) and smoking status (*P* = 0.777) between the cases and controls. However, colorectal cancer cases were significantly more likely to report a family history of cancer than the controls in their first-degree relatives (*P* \< 0.001). Among 213 colorectal cancer cases, 109 (51.2%) had colon cancer and 104 (48.8%) had rectal cancer. Regarding tumor stage, 17, 98, 66, and 32 patients classified as stage I, II, III, and IV, respectively.

The primary information and minor allele frequencies (MAFs) of the *ERCC1* and *ERCC2* SNPs are summarized in [Table 2](#t2){ref-type="table"}. The genotype distributions in the control subjects were all in agreement with the Hardy-Weinberg equilibrium for all four SNPs (*P* = 0.315 for *ERCC1* Asn118Asn, *P* = 0.426 for *ERCC1* C8092A, *P* = 0.060 for *ERCC2* Asp312Asn, and *P* = 0.573 for *ERCC2* Lys751Gln). Furthermore, the MAFs of *ERCC1* Asn118Asn, C8092A, *ERCC2* Asp312Asn, and Lys751Gln is 0.268, 0.271, 0.067, and 0.081 in the HapMap-CHB database (<http://hapmap.ncbi.nlm.nih.gov>), respectively, which were about the same as that in our study.

As shown in [Table 2](#t2){ref-type="table"}, logistic regression analysis revealed that the *ERCC1* C8092A AA genotype, but not the CA genotype, was associated with a significantly increased risk of colorectal cancer, compared with the CC genotype (*P* = 0.037) (OR = 2.50, 95% CI = 1.10--5.70 for AA versus CC; and OR = 1.47, 95% CI = 0.99--2.18 for CA versus CC). The *ERCC1* C8092A A allele was associated with the increased risk of colorectal cancer between the cases and controls (*P* = 0.012). Furthermore, a significant increased risk of colorectal cancer was found in the combined variant genotype CA/AA compared with the CC genotype (OR = 1.58, 95% CI = 1.08--2.30). However, no significant association was observed between variant genotype of the other three SNPs (*ERCC1* Asn118Asn, *ERCC2* Asp312Asn, and *ERCC2* Lys751Gln) and colorectal cancer risk.

We further evaluated the effect of the *ERCC1* C8092A polymorphism on colorectal cancer risk in the subgroups stratified by age, sex, and smoking status. As shown in [Table 3](#t3){ref-type="table"}, we found that, compared with the C8092A CC genotype, the CA/AA genotype was associated with a significantly increased risk of colorectal cancer risk among men (OR = 1.94, 95% CI = 1.16--3.23), smokers (OR = 1.69, 95% CI = 1.06--2.67), drinkers (OR = 1.62, 95% CI = 1.05--2.51), and patients with rectal cancer (OR = 1.72, 95% CI = 1.08--2.76). However, no significant gene-environment interaction was observed.

Discussion
==========

In this study, we investigated the associations between four common, potentially functional genetic variants (*ERCC1* Asn118Asn, C8092A, *ERCC2* Asp312Asn, and Lys751Gln) and the risk of colorectal cancer in a Chinese population. We found that *ERCC1* C8092A seemed to be associated with increased risk of colorectal cancer. In contrast, *ERCC1* Asn118Asn, *ERCC2* Asp312Asn and Lys751Gln SNPs did not observe any significant association with the risk of colorectal cancer in the Chinese population.

Decreased efficiency of DNA repair is considered as a crucial role in carcinogenesis as such defects accelerate genetic instability and the rate of genetic change[@b13][@b14]. As genes in the NER pathway, *ERCC1* and *ERCC2* are essential to the repair of DNA adducts in colorectal cancer[@b15][@b16][@b17][@b18]. For example, a multitude of studies have focused on the relationship between *ERCC1* and *ERCC2* polymorphisms and the prognostics for the treatment with platinum agents in colorectal cancer patients, and the meta-analyses of these data found that two SNPs in *ERCC1* and *ERCC2* might be useful prognostic factors for assessing clinical outcomes of oxaliplatin-based chemotherapies in colorectal cancer[@b17]. The mutations or polymorphisms of these two genes could alter DNA repair capacity, so it was biologically plausible to assume that the *ERCC1* and *ERCC2* polymorphisms might have functional significance in colorectal cancer. The present study investigated the associations of the *ERCC1* Asn118Asn, C8092A, *ERCC2* Asp312Asn and Lys751Gln polymorphisms with risk of colorectal cancer in the Chinese population. The *ERCC1* C8092A A allele appeared to be the risk allele for developing colorectal cancer, which was more frequent in cases than in controls. The precise mechanism for the positive association of the C8092A polymorphism remains unclear, as there are no direct functional data available for this polymorphism. Because the SNP is located at the 3′-untranslated region (3′-UTR) which can be regulated by regulatory proteins and microRNAs, the C8092A polymorphism in the 3′-UTR region could affect the stability and translation of the mRNA and further influence the amount of receptor protein expressed by a cell[@b19][@b20].

In fact, like other complex diseases, colorectal cancer is a complex trait caused by both genetic and environmental factors[@b21][@b22][@b23]. Although our results suggest that the SNPs of *ERCC2* do not directly contribute to the susceptibility to colorectal cancer, they may perhaps affect colorectal cancer risk by combining with additional polymorphisms in other genes or non-inherited risk factors. Further, a recent meta-analysis involving 22 eligible case-control studies failed to observe significant associations of these two SNPs with the risk of colorectal cancer, suggesting other genetic variants may be associated with the carcinogenesis of colorectal cancer[@b24]. Although the clinical practice of *ERCC1* and *ERCC2* polymorphisms and colorectal cancer risk is not yet established, our results with the integration of clinical, epidemiological, and genetic data could rationalize the individualized prevention. If validated, it could be effective to select the optimal intervention according to different genotypes of the *ERCC1* and *ERCC2* polymorphisms that would predict who will benefit most in the general population from colorectal cancer screening.

Several limitations of this study should be addressed. Firstly, the sample size may limit the statistical power of our study, especially for subgroup analyses. Secondly, our patients were from hospitals and controls were randomly selected from the surrounding community population, therefore inherent selection bias cannot be completely excluded. Thirdly, dietary factors appear to be among the most important determinants of colorectal cancer risk[@b25]. Because the dietary data was not complete, we did not analyze stratification of dietary factors on colorectal cancer risk. Further studies with dietary information are needed. Finally, although we had 80% power at a 0.05 or smaller with level to detect an OR of 1.80 or greater and 0.49 or smaller with an exposure frequency of 22.5% given our current study sample size (data not shown), the sample was relatively small, which greatly decreased statistical power of the analysis.

In conclusion, our results indicate that the *ERCC1* C8092A SNP may be involved in the susceptibility of colorectal cancer in the Chinese population. Future studies with larger samples and functional evaluation are warranted to validate our findings.

Methods
=======

Ethics statement
----------------

The study was approved by the institutional review board of Nanjing University of Chinese Medicine. The informed written consent was obtained from all subjects.

Study populations
-----------------

A total of 213 colorectal cancer cases and 240 cancer-free controls were included. In brief, the cases were incident colorectal cancer patients and were consecutively recruited from the Nanjing Hospital of T.C.M and Xuzhou First People Hospital, Jiangsu, China, starting in September 2010. Controls were randomly selected from a pool of healthy volunteers who visited the general health check-up center. The cancer-free control subjects were genetically unrelated to the cases and had no individual history of cancer. After written informed consent was obtained, demographic data and environmental exposure history were obtained from the patients using a standardized face-to-face questionnaire.

Genotyping
----------

Genomic DNA was extracted from a leukocyte pellet by traditional proteinase K digestion followed by phenol-chloroform extraction and ethanol precipitation. SNPs were genotyped by using the TaqMan allelic discrimination assay on the platform of 7900HT Real-time PCR System (Applied Biosystems, Foster City,CA). Genotyping was performed without knowing each subject\'s case or control status, and two negative controls (no DNA) included in each 384-well plate were used for quality control. The genotyping results were determined by using SDS 2.3 Allelic Discrimination Software (Applied Biosystems). Genotype analysis was performed by two persons independently in a blind fashion. In addition, 10% of randomly selected samples were repeated independently to verify genotyping results.

Statistical analyses
--------------------

Hardy-Weinberg equilibrium (HWE) was tested by a goodness-of-fit χ^2^-test to compare the observed genotype frequencies to the expected ones among the controls. Student\'s t-test or χ^2^-test was used to evaluate differences in the distribution of characteristics of selected variables and genotypes between the cases and controls. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated by unconditional logistic regression analysis with adjustment for age, sex, and cigarette smoking. The statistical power was calculated by using the PS software (<http://biostat.mc.vanderbilt.edu/twiki/bin/view/Main/PowerSampleSize>). All statistical analyses were performed with SPSS statistical package, version 13.0. (SPSS Inc., Chicago, IL, USA). A value of *P* \< 0.05 was taken as significant (2 tailed).
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###### Descriptive characteristics of colorectal cancer cases and controls

                              Cases (n = 213)   Controls (n = 240)    *P*           
  -------------------------- ----------------- -------------------- ------- ------- ---------
  Age (mean ± SD), years        59.9 ± 12.5        60.8 ± 15.6       0.534          
  Gender                                                                                 
  Male                              121               56.8%           140    58.3%    0.743
  Female                            92                43.2%           100    41.7%       
  Smoking habit                                                                          
  Never                             142               66.7%           163    67.9%    0.777
  Ever                              71                33.3%           77     32.1%       
  Family history of cancer                                                               
  No                                156               73.2%           221    92.1%   \<0.001
  Yes                               57                26.8%           19     7.9%        
  Tumor site                                                                             
  Colon                             109               51.2%                              
  Rectum                            104               48.8%                              
  Tumor stages                                                                           
  I                                 17                 8.0%                              
  II                                98                46.0%                              
  III                               66                31.0%                              
  IV                                32                15.0%                              

###### Genotype and allele frequencies of *ERCC1* and *ERCC2* polymorphisms among cases and controls and their associations with the risk of colorectal cancer

                       Cases   Controls   *P*   OR (95% CI)[c](#t2-fn3){ref-type="fn"}                                     
  ------------------- ------- ---------- ----- ---------------------------------------- ---------------------------------- -------------------
  *ERCC1* Asn118Asn                                                                                                                  
  CC                    117     54.9%     135                   56.3%                    0.767[a](#t2-fn1){ref-type="fn"}         1.00
  CT                    82      38.5%     86                    35.8%                                                       1.13 (0.78--1.67)
  TT                    14       6.6%     19                     7.9%                                                       0.93 (0.44--1.97)
  T allele                      25.8%                           25.8%                    0.997[b](#t2-fn2){ref-type="fn"}            
  *ERCC1* C8092A                                                                                                                     
  CC                    104     48.8%     142                   59.2%                    0.037[a](#t2-fn1){ref-type="fn"}         1.00
  CA                    91      42.7%     88                    36.7%                                                       1.47 (0.99--2.18)
  AA                    18       8.5%     10                     4.1%                                                       2.50 (1.10--5.70)
  CA/AA                 109     51.2%     98                    40.8%                    0.027[a](#t2-fn1){ref-type="fn"}   1.58 (1.08--2.30)
  A allele                      29.8%                           22.5%                    0.012[b](#t2-fn2){ref-type="fn"}            
  *ERCC2* Asp312Asn                                                                                                                  
  GG                    182     85.4%     210                   87.5%                    0.634[a](#t2-fn1){ref-type="fn"}         1.00
  GA                    26      12.2%     27                    11.3%                                                       1.16 (0.65--2.07)
  AA                     5       2.4%      3                     1.2%                                                       1.76 (0.41--7.51)
  A allele                       8.5%                            6.9%                    0.372[b](#t2-fn2){ref-type="fn"}            
  *ERCC2* Lys751Gln                                                                                                                  
  AA                    176     82.6%     201                   83.8%                    0.776[a](#t2-fn1){ref-type="fn"}         1.00
  AC                    35      16.4%     38                    15.8%                                                       1.13 (0.68--1.87)
  CC                     2       1.0%      1                     0.4%                                                       3.10 (0.27--35.4)
  C allele                       9.2%                            8.3%                    0.662[b](#t2-fn2){ref-type="fn"}            

^a^Two-sided chi-squared test for genotype distributions between cases and controls.

^b^Two-sided chi-squared test for allele frequencies between cases and controls.

^c^ORs were adjusted for age, sex, and smoking status.

###### Stratified analyses on association between the *ERCC1* C8092A polymorphism and risk of colorectal cancer

                     Cases (n = 213)   Controls (n = 240)   Adjusted OR (95%CI)[a](#t3-fn1){ref-type="fn"}       
  ----------------- ----------------- -------------------- ------------------------------------------------ ---- -------------------
  Age                                                                                                                      
  ≤60                      49                  52                                 53                         35   1.50 (0.80--2.82)
  \>60                     55                  57                                 89                         63   1.52 (0.92--2.54)
  Sex                                                                                                                      
  Male                     57                  64                                 88                         52   1.94 (1.16--3.23)
  Female                   47                  45                                 54                         46   1.20 (0.65--2.22)
  Smoking status                                                                                                           
  Never                    35                  36                                 42                         35   1.18 (0.60--2.33)
  Ever                     69                  73                                100                         63   1.69 (1.06--2.67)
  Drinking status                                                                                                          
  Never                    29                  31                                 28                         23   1.45 (0.62--3.42)
  Ever                     75                  78                                114                         75   1.62 (1.05--2.51)
  Tumor site                                                                                                               
  Colon                    56                  53                                142                         98   1.48 (0.93--2.36)
  Rectum                   48                  56                                142                         98   1.72 (1.08--2.76)

^a^ORs and *P* value were adjusted for age, sex, and smoking status.
